GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03796260
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 458
- Registration Number
- NCT03785678
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles, Los Angeles, California, United States
🇺🇸University of Southern California Medical Center, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT03747575
- Locations
- 🇺🇸
Florida Pulmonary Research Institute, LLC, Winter Park, Florida, United States
🇺🇸Skin Laser and Surgery Specialists of New York and New Jersey LLC - Interspond - PPDS, Hackensack, New Jersey, United States
🇺🇸Harmony Clinical Research, Inc, North Miami Beach, Florida, United States
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03693625
- Locations
- 🇺🇸
Allergy & Asthma Immunology Associates, Scottsdale, Arizona, United States
🇺🇸Kern Allergy Med Clinic, Inc., Bakersfield, California, United States
🇺🇸Integrated Research Group Inc, Riverside, California, United States
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT03650413
- Locations
- 🇵🇱
Endoskopia Sp. z o.o., Sopot, Poland
🇵🇱Synexus - Poznan, Poznan, Poland
🇧🇬MHAT Saint Karidad EAD, Plovdiv, Bulgaria
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT03606460
- Locations
- 🇺🇸
Dragonfly Research, LLC, Wellesley, Massachusetts, United States
🇺🇸University of Colorado; Anschutz Medical Campus Department of Neurology, Aurora, Colorado, United States
🇺🇸Cleveland Clinic Fndn, Cleveland, Ohio, United States
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT03563716
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
🇺🇸SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
🇺🇸SCRI Florida Cancer Specialists North; Research Office North Region., Saint Petersburg, Florida, United States
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- Conditions
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT03558152
- Locations
- 🇵🇱
Synexus Polska Sp. z o.o. Oddzial w Gdansku, Gda?sk, Poland
🇷🇸Clinical Hospital Center Zvezdara, Belgrade, Serbia
🇵🇱Klimed Marek Klimkiewicz, Piotrków Trybunalski, Poland
Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03451162
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT03448042
- Locations
- 🇳🇱
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇩🇰Rigshospitalet, København Ø, Denmark